% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kap:126839,
      author       = {E. J. Kap$^*$ and P. Seibold$^*$ and S. Richter and D.
                      Scherer$^*$ and N. Habermann$^*$ and Y. Balavarca and L.
                      Jansen$^*$ and N. Becker$^*$ and K. Pfütze and O.
                      Popanda$^*$ and M. Hoffmeister$^*$ and A. Ulrich and A.
                      Benner$^*$ and C. M. Ulrich$^*$ and B. Burwinkel$^*$ and H.
                      Brenner$^*$ and J. Chang-Claude$^*$},
      title        = {{G}enetic variants in {DNA} repair genes as potential
                      predictive markers for oxaliplatin chemotherapy in
                      colorectal cancer.},
      journal      = {The pharmacogenomics journal},
      volume       = {15},
      number       = {6},
      issn         = {1473-1150},
      address      = {Basingstoke},
      publisher    = {Nature Publishing Group},
      reportid     = {DKFZ-2017-02867},
      pages        = {505 - 512},
      year         = {2015},
      abstract     = {Oxaliplatin-based chemotherapy exerts its effects through
                      generating DNA damage. Hence, genetic variants in DNA repair
                      pathways could modulate treatment response. We used a
                      prospective cohort of 623 colorectal cancer patients with
                      stage II-IV disease treated with adjuvant/palliative
                      chemotherapy to comprehensively investigate 1727 genetic
                      variants in the DNA repair pathways as potential predictive
                      markers for oxaliplatin treatment. Single nucleotide
                      polymorphisms (SNP) associations with overall survival and
                      recurrence-free survival were assessed using a Cox
                      regression model. Pathway analysis was performed using the
                      gamma method. Patients carrying variant alleles of rs3783819
                      (MNAT1) and rs1043953 (XPC) experienced a longer overall
                      survival after treatment with oxaliplatin than patients who
                      did not carry the variant allele, while the opposite
                      association was found in patients who were not treated with
                      oxaliplatin (false discovery rate-adjusted P-values for
                      heterogeneity 0.0047 and 0.0237, respectively). The
                      nucleotide excision repair (NER) pathway was found to be
                      most likely associated with overall survival in patients who
                      received oxaliplatin (P-value=0.002). Our data show that
                      genetic variants in the NER pathway are potentially
                      predictive of treatment response to oxaliplatin.},
      keywords     = {Biomarkers, Tumor (NLM Chemicals) / DNA-Binding Proteins
                      (NLM Chemicals) / Organoplatinum Compounds (NLM Chemicals) /
                      oxaliplatin (NLM Chemicals)},
      cin          = {C020 / G110 / C070 / C060 / C010 / C080 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331 / I:(DE-He78)G110-20160331 /
                      I:(DE-He78)C070-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)C010-20160331 / I:(DE-He78)C080-20160331 /
                      I:(DE-He78)L101-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25778469},
      pmc          = {pmc:PMC4573779},
      doi          = {10.1038/tpj.2015.8},
      url          = {https://inrepo02.dkfz.de/record/126839},
}